ArticleClinics (Sao Paulo, Brazil)2026
Biochemical insights and microRNA profiling via next-generation sequencing in moderate and severe COVID-19 cases.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 remains the most devastating and challenging viral disease in human history
objectiveThis study explores the biochemical and host microRNA (miRNA) response to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection and explores how DE miRNAs alter molecular pathways to identify potential prognostic and therapeutic biomarkers.
methodsBiochemical profiling on automated chemistry analyzers and circulating miRNA profiling by Next Generation Sequencing were performed in moderate (ward) and severe (ICU) patients of COVID-19. miRNA Differential Expression (DE) was analyzed in ICU vs. Control and Ward vs. Control Groups. Statistical comparison of biochemical variables amongst ICU, Ward, and Control groups was done on SPSS by applying the Kruskal-Wallis test; p-value < 0.05 was considered significant. miRNA DE analysis was performed with the help of a bioinformatics tool, DESeq2. A False Discovery Rate (FDR) adjusted p-value < 0.05 was considered to be significant.
resultsMost biochemical parameters were significantly and proportionately altered with respect to the severity of the disease. Patients showed compromised renal, hepatic, and cardiac function, as well as deranged blood pictures and elevated inflammatory markers (CRP, IL-6, LDH, and Ferritin). miRNA Differential Expression (DE) when analyzed in both study groups, 102 DE miRNAs were found in the ICU vs. Control group, of which miR-423-5p was significantly upregulated, and miR-744-5p was significantly downregulated. Whereas, in the Ward vs. control group, out of 91 DE miRNAs, only miR-486-5p was observed to be significantly upregulated. Gene targets of these three miRNAs were further explored along with their cellular pathways. Literature suggests that these affected cellular pathways converge on the stimulation of the NF-κB pathway. Biochemical evaluation of COVID-19 cases reveals major disease severity predictors like raised inflammatory markers CRP, IL-6, LDH, elevated organ function tests and deranged hematological profiles.
conclusionThree differentially expressed miRNAs were observed that might be involved in the activation of NF-κB, which acts as a major modulator of inflammation in response to SARS-CoV-2 infection. The miRNA findings are preliminary and hypothesis-generating, only requiring independent validation e.g., qPCR in a larger cohort. The probable theragnostic potential of these miRNAs may be clinically explored further by the use of miRNA mimics or miRNA inhibitors that may change the adversity associated with this virus altogether.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.